Literature DB >> 16227649

Effects of acute and chronic treatment with magnesium in the forced swim test in rats.

Ewa Poleszak1, Piotr Wlaź, Ewa Kedzierska, Maria Radziwon-Zaleska, Andrzej Pilc, Sylwia Fidecka, Gabriel Nowak.   

Abstract

The antidepressant-like activity of magnesium, the non-specific N-methyl-D-aspartate glutamate receptor antagonist, in the mice forced swim test was demonstrated previously. In the present study, the effects of this biometal were studied in the rat forced swim test. Magnesium (MgCl2) at doses ranging from 15 to 50 mg Mg/kg reduced the immobility time in the forced swim test, thus exerting antidepressant-like activity. To evaluate tolerance to this effect, we also performed experiments with the following acute/chronic magnesium treatment schedule: chronic saline and saline challenge at 0.5 h before behavioral experiments (S + S), chronic saline and magnesium challenge (S + Mg), chronic magnesium and saline challenge (Mg + S), chronic magnesium and magnesium challenge (Mg + Mg). The antidepressant-like effect of magnesium was demonstrated in the group treated acutely with magnesium (S + Mg) but not in the chronically treated group (Mg + S) and (Mg + Mg). It is interesting to note that in Mg + Mg group serum concentration of magnesium was quite similar to the S + Mg group (6.44 vs. 6.08 mg/100 ml, respectively), which displayed antidepressant-like effect. The results confirmed that magnesium administered acutely induced the antidepressant-like effects also in rats. However, contrary to mice, chronic treatment with magnesium induced tolerance to this effect in rats.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16227649

Source DB:  PubMed          Journal:  Pharmacol Rep        ISSN: 1734-1140            Impact factor:   3.024


  7 in total

1.  Evidence for the involvement of NMDA receptors in the antidepressant-like effect of nicotine in mouse forced swimming and tail suspension tests.

Authors:  Arya Haj-Mirzaian; Nastaran Kordjazy; Arvin Haj-Mirzaian; Sattar Ostadhadi; Mehdi Ghasemi; Shayan Amiri; Mehrdad Faizi; AhmadReza Dehpour
Journal:  Psychopharmacology (Berl)       Date:  2015-07-15       Impact factor: 4.530

2.  Modulation of antidepressant-like activity of magnesium by serotonergic system.

Authors:  E Poleszak
Journal:  J Neural Transm (Vienna)       Date:  2007-04-20       Impact factor: 3.575

3.  A complex interaction between glycine/NMDA receptors and serotonergic/noradrenergic antidepressants in the forced swim test in mice.

Authors:  Ewa Poleszak; Piotr Wlaź; Bernadeta Szewczyk; Aleksandra Wlaź; Regina Kasperek; Andrzej Wróbel; Gabriel Nowak
Journal:  J Neural Transm (Vienna)       Date:  2011-04-02       Impact factor: 3.575

4.  Traxoprodil, a selective antagonist of the NR2B subunit of the NMDA receptor, potentiates the antidepressant-like effects of certain antidepressant drugs in the forced swim test in mice.

Authors:  Ewa Poleszak; Weronika Stasiuk; Aleksandra Szopa; Elżbieta Wyska; Anna Serefko; Anna Oniszczuk; Sylwia Wośko; Katarzyna Świąder; Piotr Wlaź
Journal:  Metab Brain Dis       Date:  2016-02-29       Impact factor: 3.584

5.  Influence of the selective antagonist of the NR2B subunit of the NMDA receptor, traxoprodil, on the antidepressant-like activity of desipramine, paroxetine, milnacipran, and bupropion in mice.

Authors:  Weronika Stasiuk; Aleksandra Szopa; Anna Serefko; Elżbieta Wyska; Katarzyna Świąder; Jarosław Dudka; Piotr Wlaź; Ewa Poleszak
Journal:  J Neural Transm (Vienna)       Date:  2016-11-29       Impact factor: 3.575

Review 6.  Impact of Supplementation and Nutritional Interventions on Pathogenic Processes of Mood Disorders: A Review of the Evidence.

Authors:  Cara T Hoepner; Roger S McIntyre; George I Papakostas
Journal:  Nutrients       Date:  2021-02-26       Impact factor: 5.717

7.  The interactive effects of ketamine and magnesium upon depressive-like pathology.

Authors:  Sara Razmjou; Darcy Litteljohn; Chris Rudyk; Shuaib Syed; Melanie Clarke; Rowan Pentz; Zach Dwyer; Shawn Hayley
Journal:  Neuropsychiatr Dis Treat       Date:  2016-09-08       Impact factor: 2.570

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.